These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8204486)

  • 41. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.
    Woodley DT; Krueger GG; Jorgensen CM; Fairley JA; Atha T; Huang Y; Chan L; Keene DR; Chen M
    J Invest Dermatol; 2003 Nov; 121(5):1021-8. PubMed ID: 14708601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dominant dystrophic epidermolysis bullosa (Pasini) caused by a novel glycine substitution mutation in the type VII collagen gene (COL7A1).
    Jonkman MF; Moreno G; Rouan F; Oranje AP; Pulkkinen L; Uitto J
    J Invest Dermatol; 1999 May; 112(5):815-7. PubMed ID: 10233777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidermolysis bullosa in Finland. Clinical features, morphology and relation to collagen metabolism.
    Kero M
    Acta Derm Venereol Suppl (Stockh); 1984; 110():1-51. PubMed ID: 6331034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Role of Collagen IV and Cytokeratin 5/6 Immunohistochemistry in Identifying Subtypes of Hereditary Epidermolysis Bullosa.
    Alhumidi A
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):586-590. PubMed ID: 27941563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Transient bullous lesions - a case of de novo mutation in the COL7A1 gene in patient with Epidermolysis bullosa dystrophica].
    Sobczyńska-Tomaszewska A; Wertheim-Tysarowska K; Kosykowska E; Kowalewski C
    Med Wieku Rozwoj; 2011; 15(2):119-25. PubMed ID: 22002042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Compound heterozygosity for silent and dominant glycine substitution mutations in COL7A1 leads to a marked transient intracytoplasmic retention of procollagen VII and a moderately severe dystrophic epidermolysis bullosa phenotype.
    Shimizu H; Hammami-Hauasli N; Hatta N; Nishikawa T; Bruckner-Tuderman L
    J Invest Dermatol; 1999 Sep; 113(3):419-21. PubMed ID: 10469344
    [No Abstract]   [Full Text] [Related]  

  • 47. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.
    Wong T; Gammon L; Liu L; Mellerio JE; Dopping-Hepenstal PJ; Pacy J; Elia G; Jeffery R; Leigh IM; Navsaria H; McGrath JA
    J Invest Dermatol; 2008 Sep; 128(9):2179-89. PubMed ID: 18385758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EPIDERMOLYSIS BULLOSA. WITH A CASE REPORT ON EPIDERMOLYSIS BULLOSA DYSTROPHICA IN ONE OF A PAIR OF TWINS.
    PATNAIK R
    Indian J Pediatr; 1964 Mar; 31():81-4. PubMed ID: 14147902
    [No Abstract]   [Full Text] [Related]  

  • 49. Inversa dystrophic epidermolysis bullosa is caused by missense mutations at specific positions of the collagenic domain of collagen type VII.
    Chiaverini C; Charlesworth AV; Youssef M; Cuny JF; Rabia SH; Lacour JP; Meneguzzi G
    J Invest Dermatol; 2010 Oct; 130(10):2508-11. PubMed ID: 20555349
    [No Abstract]   [Full Text] [Related]  

  • 50. Dystrophic epidermolysis bullosa with one dominant and one recessive mutation of the COL7A1 gene in a child with deafness.
    Weinel S; Lucky AW; Uitto J; Pfendner EG; Choo D
    Pediatr Dermatol; 2008; 25(2):210-4. PubMed ID: 18429782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Late-onset inversa recessive dystrophic epidermolysis bullosa caused by glycine substitutions in collagen type VII.
    Leverkus M; Ambach A; Hoefeld-Fegeler M; Kohlhase J; Schmidt E; Schumann H; Has C; Gollnick H
    Br J Dermatol; 2011 May; 164(5):1104-6. PubMed ID: 21275939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural gene therapy in dystrophic epidermolysis bullosa.
    van den Akker PC; Nijenhuis M; Meijer G; Hofstra RM; Jonkman MF; Pasmooij AM
    Arch Dermatol; 2012 Feb; 148(2):213-6. PubMed ID: 22004882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel COL7A1 splice site mutation in severe generalized recessive dystrophic epidermolysis bullosa.
    Jeon IK; Kim SE; Kim SC
    J Dermatol; 2014 Apr; 41(4):350-1. PubMed ID: 24533879
    [No Abstract]   [Full Text] [Related]  

  • 54. A type VII collagen subdomain mutant is thermolabile and shows enhanced proteolytic degradability - Implications for the pathogenesis of recessive dystrophic epidermolysis bullosa?
    Windler C; Hermsdorf U; Brinckmann J; Seeger K
    Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):52-59. PubMed ID: 27989960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Denuded congenital lesions: recessive dystrophic epidermolysis bullosa.
    Fleming KF; Wu JJ; Dyson SW; Dadras SS; Metz BJ
    Dermatol Online J; 2009 Apr; 15(4):4. PubMed ID: 19450397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line.
    Mecklenbeck S; Compton SH; Mejía JE; Cervini R; Hovnanian A; Bruckner-Tuderman L; Barrandon Y
    Hum Gene Ther; 2002 Sep; 13(13):1655-62. PubMed ID: 12228020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The genetics of inherited bullous diseases of the skin. Future aspects in perinatal and prenatal diagnosis].
    Uitto J
    Duodecim; 1996; 112(5):368-75. PubMed ID: 10592597
    [No Abstract]   [Full Text] [Related]  

  • 58. Epidermolysis Bullosa Pruriginosa Treated With Baricitinib.
    Jiang X; Wang H; Lee M; Lin Z
    JAMA Dermatol; 2021 Oct; 157(10):1243-1244. PubMed ID: 34468689
    [No Abstract]   [Full Text] [Related]  

  • 59. Autoimmunity and Cytokine Imbalance in Inherited Epidermolysis Bullosa.
    Esposito S; Guez S; Orenti A; Tadini G; Scuvera G; Corti L; Scala A; Biganzoli E; Berti E; Principi N
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High concordance between clinical diagnosis of epidermolysis bullosa and immunofluorescence with a small, well-matched antibody panel.
    Meester I; Igoucheva O; Alexeev V; South A; Moreno-Treviño MG; Salas-Alanis JC
    Australas J Dermatol; 2018 Feb; 59(1):73-76. PubMed ID: 28707324
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.